David Hong - Spero Therapeutics Senior Development
| SPRO Stock | USD 2.38 0.01 0.42% |
Executive
David Hong is Senior Development of Spero Therapeutics
| Address | 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 |
| Phone | 857 242 1600 |
| Web | https://sperotherapeutics.com |
Spero Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2977) % which means that it has lost $0.2977 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.953) %, meaning that it created substantial loss on money invested by shareholders. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of February 2026, Return On Tangible Assets is likely to drop to -0.59. In addition to that, Return On Capital Employed is likely to drop to -1.13. At this time, Spero Therapeutics' Debt To Assets are very stable compared to the past year. As of the 12th of February 2026, Fixed Asset Turnover is likely to grow to 14.56, while Total Assets are likely to drop about 120.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris McChalicher | Seres Therapeutics | N/A | |
| Paul CPA | Actuate Therapeutics Common | 58 | |
| Ian BSc | Corbus Pharmaceuticals Holding | 53 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Dennis MD | Seres Therapeutics | N/A | |
| Trisha Fitzmaurice | VistaGen Therapeutics | N/A | |
| Erik MD | VistaGen Therapeutics | N/A | |
| John Doyle | Cognition Therapeutics | 49 | |
| Robert Juba | Inovio Pharmaceuticals | N/A | |
| Nick MBA | VistaGen Therapeutics | 53 | |
| Thomas Hong | Inovio Pharmaceuticals | N/A | |
| MBA MA | Inovio Pharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| MS JD | Corbus Pharmaceuticals Holding | N/A | |
| Robert Gagnon | Opus Genetics | 52 | |
| Michelle Wellington | VistaGen Therapeutics | N/A | |
| Jenny Kobin | Opus Genetics | N/A | |
| Michael MD | Inovio Pharmaceuticals | 60 | |
| Mark Flather | VistaGen Therapeutics | N/A | |
| Robert JD | Inovio Pharmaceuticals | 52 | |
| Sally Tucker | Opus Genetics | N/A | |
Management Performance
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.3 |
Spero Therapeutics Leadership Team
Elected by the shareholders, the Spero Therapeutics' board of directors comprises two types of representatives: Spero Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spero. The board's role is to monitor Spero Therapeutics' management team and ensure that shareholders' interests are well served. Spero Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spero Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satyavrat CFA, CFO Treasurer | ||
| James Brady, Chief Officer | ||
| Ted Jenkins, VP Relations | ||
| Ian Critchley, Head Microbiology | ||
| Sheila Finan, Senior Controller | ||
| John Raymond, Senior Operations | ||
| Timothy Keutzer, Senior Vice President - Development | ||
| Angela MD, VP Devel | ||
| MBA MD, President, CoFounder | ||
| Tamara LLM, Chief Secretary | ||
| Susannah Walpole, Head Operations | ||
| Esther Rajavelu, Interim President | ||
| David Hong, Senior Development |
Spero Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spero Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (1.08) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 88.26 M | ||||
| Shares Outstanding | 56.34 M | ||||
| Shares Owned By Insiders | 23.34 % | ||||
| Shares Owned By Institutions | 16.58 % | ||||
| Number Of Shares Shorted | 941.66 K | ||||
| Price To Earning | 81.20 X |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Spero Stock
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.